A Review of Anti-IL-5 Therapies for Eosinophilic Granulomatosis with Polyangiitis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Review of Anti-IL-5 Therapies for Eosinophilic Granulomatosis with Polyangiitis
Authors
Keywords
-
Journal
ADVANCES IN THERAPY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-09-24
DOI
10.1007/s12325-022-02307-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis
- (2022) Peter C Grayson et al. ANNALS OF THE RHEUMATIC DISEASES
- Increased Circulating Cell-Free DNA in Eosinophilic Granulomatosis With Polyangiitis: Implications for Eosinophil Extracellular Traps and Immunothrombosis
- (2022) Teppei Hashimoto et al. Frontiers in Immunology
- ANCA-Associated Vasculitic Neuropathies: A Review
- (2022) Haruki Koike et al. Neurology and Therapy
- Therapeutic advances in eosinophilic granulomatosis with polyangiitis
- (2022) Julia A. Ford et al. CURRENT OPINION IN RHEUMATOLOGY
- In vivo visualization of eosinophil secretion in eosinophilic granulomatosis with polyangiitis: An ultrastructural study
- (2022) Haruki Koike et al. ALLERGOLOGY INTERNATIONAL
- Early ultrastructural lesions of anti‐neutrophil cytoplasmic antibody‐ versus complement‐associated vasculitis
- (2022) Haruki Koike et al. NEUROPATHOLOGY
- Efficacy and Safety of Reslizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA)
- (2021) Laurie Manka et al. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
- Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome)
- (2021) Alessandra Bettiol et al. EUROPEAN RESPIRATORY JOURNAL
- Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2021) Joseph K Han et al. Lancet Respiratory Medicine
- From DREAM to REALITI‐A and beyond: Mepolizumab for the treatment of eosinophil‐driven diseases
- (2021) Ian D. Pavord et al. ALLERGY
- 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
- (2021) Sharon A. Chung et al. Arthritis & Rheumatology
- Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study
- (2021) Alessandra Bettiol et al. Arthritis & Rheumatology
- The prevalence, burden of disease, and healthcare utilization of patients with eosinophilic granulomatosis with polyangiitis in Japan: a retrospective, descriptive cohort claims database study
- (2021) Ken-ei Sada et al. Modern Rheumatology
- Novel Targets for Drug Use in Eosinophilic Granulomatosis With Polyangiitis
- (2021) Martina Uzzo et al. Frontiers in Medicine
- The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis
- (2020) Hiroyuki Nagase et al. ALLERGOLOGY INTERNATIONAL
- Type 2 immunity in the skin and lungs
- (2020) Cezmi A. Akdis et al. ALLERGY
- Differential clinicopathologic features of EGPA-associated neuropathy with and without ANCA
- (2020) Ryoji Nishi et al. NEUROLOGY
- Management of ANCA associated vasculitis
- (2020) Zachary S Wallace et al. BMJ-British Medical Journal
- Early benralizumab for eosinophilic myocarditis in eosinophilic granulomatosis with polyangiitis
- (2020) Stefania Colantuono et al. ALLERGOLOGY INTERNATIONAL
- Benralizumab as a glucocorticoid-sparing treatment option for severe asthma in eosinophilic granulomatosis with polyangiitis
- (2020) Roberto Padoan et al. Journal of Allergy and Clinical Immunology-In Practice
- Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial
- (2020) Florence Roufosse et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis
- (2020) Vamsi P. Guntur et al. Journal of Allergy and Clinical Immunology-In Practice
- How to detect eosinophil ETosis (EETosis) and extracellular traps
- (2020) Mineyo Fukuchi et al. ALLERGOLOGY INTERNATIONAL
- The multiple functions and subpopulations of eosinophils in tissues under steady-state and pathological conditions
- (2020) Akira Kanda et al. ALLERGOLOGY INTERNATIONAL
- Decrease in MPO-ANCA after administration of benralizumab in eosinophilic granulomatosis with polyangiitis
- (2019) Kenchi Takenaka et al. ALLERGOLOGY INTERNATIONAL
- Eosinophil-platelet interactions promote atherosclerosis and stabilize thrombosis by eosinophil extracellular traps
- (2019) Charlotte Marx et al. BLOOD
- Prevalence of Eosinophilic Granulomatosis With Polyangiitis and Associated Health Care Utilization Among Patients With Concomitant Asthma in US Commercial Claims Database
- (2019) Mugdha Gokhale et al. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
- Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status
- (2019) Paul A Lyons et al. Nature Communications
- Contemporary understanding of the secretory granules in human eosinophils
- (2018) Rossana C. N. Melo et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Enzymatic lipid oxidation by eosinophils propagates coagulation, hemostasis, and thrombotic disease
- (2017) Stefan Uderhardt et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
- (2017) Michael E. Wechsler et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma
- (2017) Parameswaran Nair et al. NEW ENGLAND JOURNAL OF MEDICINE
- EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
- (2016) M Yates et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
- (2016) Eugene R Bleecker et al. LANCET
- Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
- (2016) J Mark FitzGerald et al. LANCET
- Long-Term Followup of a Multicenter Cohort of 101 Patients With Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss)
- (2016) Cécile-Audrey Durel et al. ARTHRITIS CARE & RESEARCH
- Intravenous Immunoglobulin as an Immunomodulating Agent in Antineutrophil Cytoplasmic Antibody-Associated Vasculitides: A French Nationwide Study of Ninety-Two Patients
- (2016) Etienne Crickx et al. Arthritis & Rheumatology
- Eosinophilic granulomatosis with polyangiitis (Churg–Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management
- (2015) Matthieu Groh et al. European Journal of Internal Medicine
- Intravenous immunoglobulin for chronic residual peripheral neuropathy in eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome): a multicenter, double-blind trial
- (2015) Haruki Koike et al. JOURNAL OF NEUROLOGY
- Group 2 innate lymphoid cells and asthma
- (2015) Hiroki Kabata et al. ALLERGOLOGY INTERNATIONAL
- Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials
- (2015) Mario Castro et al. Lancet Respiratory Medicine
- Electron microscopy elucidates eosinophil degranulation patterns in patients with eosinophilic esophagitis
- (2014) Hedieh Saffari et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
- (2014) Hector G. Ortega et al. NEW ENGLAND JOURNAL OF MEDICINE
- The consequences of not having eosinophils
- (2013) G. J. Gleich et al. ALLERGY
- Targeting Interleukin-5 in Refractory and Relapsing Churg–Strauss Syndrome
- (2013) Frank Moosig et al. ANNALS OF INTERNAL MEDICINE
- Clinicopathological features of neuropathy in anti-neutrophil cytoplasmic antibody-associated vasculitis
- (2013) Haruki Koike et al. Clinical and Experimental Nephrology
- Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia
- (2013) Michel Laviolette et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Type 2 innate lymphoid cells control eosinophil homeostasis
- (2013) Jesse C. Nussbaum et al. NATURE
- 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides
- (2012) J. C. Jennette et al. ARTHRITIS AND RHEUMATISM
- Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort
- (2012) Cloé Comarmond et al. ARTHRITIS AND RHEUMATISM
- Anti-neutrophil cytoplasmic autoantibodies: Methodological aspects and clinical significance in systemic vasculitis
- (2012) Antonella Radice et al. AUTOIMMUNITY REVIEWS
- Antineutrophil cytoplasmic autoantibodies and myeloperoxidase autoantibodies in clinical expression of Churg-Strauss syndrome
- (2012) Bridget Healy et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
- (2012) Ian D Pavord et al. LANCET
- Infection-induced NETosis is a dynamic process involving neutrophil multitasking in vivo
- (2012) Bryan G Yipp et al. NATURE MEDICINE
- Increased production of IL-5 and dominant Th2-type response in airways of Churg–Strauss syndrome patients
- (2012) Bogdan Jakiela et al. RHEUMATOLOGY
- Reslizumab for Poorly Controlled, Eosinophilic Asthma
- (2011) Mario Castro et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor
- (2011) N. A. Molfino et al. CLINICAL AND EXPERIMENTAL ALLERGY
- Benralizumab – a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity – a novel approach for the treatment of asthma
- (2011) Aasia Ghazi et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- The American College of Rheumatology 1990 criteria for the classification of churg-strauss syndrome (allergic granulomatosis and angiitis)
- (2010) Alfonse T. Masi et al. ARTHRITIS AND RHEUMATISM
- Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti–IL-5 receptor α antibody, in a phase I study of subjects with mild asthma
- (2010) William W. Busse et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Sustained response to mepolizumab in refractory Churg-Strauss syndrome
- (2010) Jean-Emmanuel Kahn et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome
- (2010) Sophia Kim et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function
- (2010) Roland Kolbeck et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Netting neutrophils in autoimmune small-vessel vasculitis
- (2009) Kai Kessenbrock et al. NATURE MEDICINE
- Eosinophil granules function extracellularly as receptor-mediated secretory organelles
- (2008) J. S. Neves et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started